AU612168B2 - Novel process for purification of hepatitis a virions - Google Patents
Novel process for purification of hepatitis a virions Download PDFInfo
- Publication number
- AU612168B2 AU612168B2 AU20518/88A AU2051888A AU612168B2 AU 612168 B2 AU612168 B2 AU 612168B2 AU 20518/88 A AU20518/88 A AU 20518/88A AU 2051888 A AU2051888 A AU 2051888A AU 612168 B2 AU612168 B2 AU 612168B2
- Authority
- AU
- Australia
- Prior art keywords
- hav
- aqueous phase
- cells
- extracting
- attenuated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 title claims abstract description 38
- 238000000746 purification Methods 0.000 title description 10
- 210000002845 virion Anatomy 0.000 title description 9
- 208000006454 hepatitis Diseases 0.000 title description 2
- 231100000283 hepatitis Toxicity 0.000 title description 2
- 230000002238 attenuated effect Effects 0.000 claims abstract description 19
- 229920001223 polyethylene glycol Polymers 0.000 claims description 29
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 claims description 28
- 239000002202 Polyethylene glycol Substances 0.000 claims description 27
- 239000008346 aqueous phase Substances 0.000 claims description 25
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 24
- 239000008188 pellet Substances 0.000 claims description 19
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical group ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 11
- 239000006166 lysate Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 238000000527 sonication Methods 0.000 claims description 9
- 238000003306 harvesting Methods 0.000 claims description 7
- 238000004255 ion exchange chromatography Methods 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 claims description 6
- 238000001556 precipitation Methods 0.000 claims description 6
- 238000002255 vaccination Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 5
- 230000002934 lysing effect Effects 0.000 claims description 5
- 229920003170 water-soluble synthetic polymer Polymers 0.000 claims description 4
- 239000012071 phase Substances 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 241000709721 Hepatovirus A Species 0.000 abstract description 59
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 229960005486 vaccine Drugs 0.000 abstract description 5
- 238000013341 scale-up Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 34
- 239000000872 buffer Substances 0.000 description 14
- 238000007792 addition Methods 0.000 description 12
- 238000003260 vortexing Methods 0.000 description 12
- 238000000605 extraction Methods 0.000 description 9
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 238000005349 anion exchange Methods 0.000 description 5
- 239000013592 cell lysate Substances 0.000 description 5
- 230000009089 cytolysis Effects 0.000 description 5
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 239000002518 antifoaming agent Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 208000005252 hepatitis A Diseases 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 229920002271 DEAE-Sepharose Polymers 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 238000001641 gel filtration chromatography Methods 0.000 description 3
- 238000002523 gelfiltration Methods 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- -1 methylene chloride Chemical class 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000709664 Picornaviridae Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- OSQPUMRCKZAIOZ-UHFFFAOYSA-N carbon dioxide;ethanol Chemical compound CCO.O=C=O OSQPUMRCKZAIOZ-UHFFFAOYSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000011005 laboratory method Methods 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000007790 scraping Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- JVIPLYCGEZUBIO-UHFFFAOYSA-N 2-(4-fluorophenyl)-1,3-dioxoisoindole-5-carboxylic acid Chemical compound O=C1C2=CC(C(=O)O)=CC=C2C(=O)N1C1=CC=C(F)C=C1 JVIPLYCGEZUBIO-UHFFFAOYSA-N 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 101100459438 Caenorhabditis elegans nac-1 gene Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 229920001425 Diethylaminoethyl cellulose Polymers 0.000 description 1
- 208000037319 Hepatitis infectious Diseases 0.000 description 1
- 101710121996 Hexon protein p72 Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000000856 sucrose gradient centrifugation Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/29—Antimony or bismuth compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32451—Methods of production or purification of viral material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Catalysts (AREA)
- Physical Water Treatments (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Bidet-Like Cleaning Device And Other Flush Toilet Accessories (AREA)
- Non-Flushing Toilets (AREA)
- Photoreceptors In Electrophotography (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Devices That Are Associated With Refrigeration Equipment (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8272087A | 1987-08-06 | 1987-08-06 | |
| US082720 | 1987-08-06 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2051888A AU2051888A (en) | 1989-03-23 |
| AU612168B2 true AU612168B2 (en) | 1991-07-04 |
Family
ID=22173006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU20518/88A Expired AU612168B2 (en) | 1987-08-06 | 1988-08-05 | Novel process for purification of hepatitis a virions |
Country Status (16)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU637114B2 (en) * | 1989-06-14 | 1993-05-20 | University Of Birmingham, The | Method of preparing vaccines against rna viruses |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2047041A1 (en) * | 1990-07-18 | 1992-01-19 | John A. Lewis | Process for purification of hepatitis-a virus capsids |
| JPH0834362B2 (ja) * | 1991-03-08 | 1996-03-29 | ローム株式会社 | 電気部品取り外し機 |
| GB9111230D0 (en) * | 1991-05-24 | 1991-07-17 | Wellcome Found | Virus production |
| US5506129A (en) * | 1991-05-24 | 1996-04-09 | Evans Medical Limited | Virus production |
| IT1248075B (it) * | 1991-06-18 | 1995-01-05 | Sclavo Spa | Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono. |
| FR2686084B1 (fr) * | 1992-01-10 | 1995-12-22 | Bioprojet Soc Civ | Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques. |
| USRE37303E1 (en) * | 1992-01-10 | 2001-07-31 | Institut National Del La Sante Et De La Recherche Medicale | Imidazole compounds and their therapeutic applications |
| DZ1706A1 (fr) | 1992-08-07 | 2002-02-17 | Merck & Co Inc | Vaccin contre le virus de l'hepatite a. |
| FR2696748B1 (fr) * | 1992-10-14 | 1994-12-30 | Pasteur Merieux Serums Vacc | Procédé de préparation d'antigènes et de vaccins de l'hépatite A (HAV). |
| HRP950097A2 (en) | 1994-03-08 | 1997-06-30 | Merck & Co Inc | Hepatitis a virus culture process |
| CA2186034C (en) * | 1994-03-22 | 2002-11-26 | Michael E. Hrinda | Highly efficient production and isolation of viral particles |
| CA2625279A1 (en) | 1995-08-30 | 1997-03-06 | Genzyme Corporation | Chromatographic purification of adenovirus and aav |
| US20080261289A1 (en) * | 1996-12-13 | 2008-10-23 | Schering-Plough Corporation | Compositions comprising viruses and methods for concentrating virus preparations |
| US6261823B1 (en) | 1996-12-13 | 2001-07-17 | Schering Corporation | Methods for purifying viruses |
| US6544769B1 (en) * | 1996-12-13 | 2003-04-08 | Schering Corporation | Compostions comprising viruses and methods for concentrating virus preparations |
| US6783939B2 (en) * | 2000-07-07 | 2004-08-31 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified HIV genes for use in vaccines |
| KR100762477B1 (ko) * | 2001-05-31 | 2007-10-02 | 주식회사 포스코 | 고로의 출선구 개공장치 |
| AU2002327614B2 (en) * | 2001-09-06 | 2007-12-06 | Alphavax, Inc. | Alphavirus replicon vector systems |
| WO2004016222A2 (en) * | 2002-08-16 | 2004-02-26 | Ohio University | Hepatitis c viral-like particle purification |
| WO2004055166A2 (en) * | 2002-12-13 | 2004-07-01 | Alphavax, Inc. | Multi-antigenic alphavirus replicon particles and methods |
| BRPI0408424B8 (pt) * | 2003-03-20 | 2021-05-25 | Alphavax Inc | ácido nucleico de replicon recombinante, população de partículas de alfa-vírus infecciosas e defeituosas, composição farmacêutica, partícula de alfa-vírus, célula microbiana e método in vitro para produzir partículas de alfa-vírus infecciosas e defeituosas |
| DE602004021260D1 (de) * | 2003-07-11 | 2009-07-09 | Alphavax Inc | Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren |
| JP5602624B2 (ja) * | 2007-06-21 | 2014-10-08 | アルファバックス， インコーポレイテッド | αウイルス構造タンパク質の発現のためのプロモーターレスカセット |
| CN102985536B (zh) | 2010-04-14 | 2017-12-05 | Emd密理博公司 | 生产高效价、高纯度的病毒母液的方法及使用其的方法 |
| MY192159A (en) * | 2015-10-15 | 2022-08-03 | Biocon Ltd | Method for detecting neutralizing antibodies against recombinant human insulin in human serum |
| EP3695849A1 (en) | 2019-02-13 | 2020-08-19 | Mediagnost Gesellschaft für Forschung und Herstellung von Diagnostika GmbH | Method for extracting hepatitis a virus (hav) antigen from cell culture |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7216091A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1971-12-03 | 1973-06-05 | ||
| US3919044A (en) * | 1973-03-28 | 1975-11-11 | Armour Pharma | Processes for concentrating and purifying viruses and viral antigens |
| US3994870A (en) * | 1974-01-31 | 1976-11-30 | The Community Blood Council Of Greater New York, Inc. | Purification of hepatitis B surface antigen |
| FR2398504A1 (fr) * | 1977-07-29 | 1979-02-23 | Tours Inst Virologie | Culture de virus de l'hepatite a, in vitro. application a la production d'un antigene reactif, d'immunserums specifiques et de vaccins contre l'hepatite a |
| US4164566A (en) * | 1978-08-17 | 1979-08-14 | Merck & Co., Inc. | Hepatitis a virus cell culture in vitro |
| US4894228A (en) * | 1982-04-07 | 1990-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine against hepatitis A virus |
| US4614793A (en) * | 1983-10-14 | 1986-09-30 | Merck & Co., Inc. | Hepatitis A--subunit antigen |
| US4683294A (en) * | 1985-04-03 | 1987-07-28 | Smith Kline Rit, S.A. | Process for the extraction and purification of proteins from culture media producing them |
| IT1248075B (it) * | 1991-06-18 | 1995-01-05 | Sclavo Spa | Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono. |
-
1988
- 1988-07-27 NZ NZ225583A patent/NZ225583A/en unknown
- 1988-07-28 IL IL87257A patent/IL87257A0/xx not_active IP Right Cessation
- 1988-08-01 EP EP88307100A patent/EP0302692B1/en not_active Expired - Lifetime
- 1988-08-01 AT AT88307100T patent/ATE84067T1/de not_active IP Right Cessation
- 1988-08-01 ES ES88307100T patent/ES2042751T3/es not_active Expired - Lifetime
- 1988-08-01 DE DE8888307100T patent/DE3877082T2/de not_active Expired - Lifetime
- 1988-08-03 JP JP63194324A patent/JPH0648980B2/ja not_active Expired - Lifetime
- 1988-08-03 PT PT88178A patent/PT88178B/pt active IP Right Grant
- 1988-08-04 ZA ZA885726A patent/ZA885726B/xx unknown
- 1988-08-04 KR KR1019880009926A patent/KR970001711B1/ko not_active Expired - Lifetime
- 1988-08-05 IE IE240788A patent/IE61294B1/en not_active IP Right Cessation
- 1988-08-05 AU AU20518/88A patent/AU612168B2/en not_active Expired
- 1988-08-05 DK DK198804379A patent/DK173215B1/da not_active IP Right Cessation
-
1992
- 1992-10-28 US US07/967,920 patent/US5521082A/en not_active Expired - Lifetime
-
1993
- 1993-02-25 GR GR930400394T patent/GR3007158T3/el unknown
-
1995
- 1995-10-20 CY CY177395A patent/CY1773A/xx unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU637114B2 (en) * | 1989-06-14 | 1993-05-20 | University Of Birmingham, The | Method of preparing vaccines against rna viruses |
Also Published As
| Publication number | Publication date |
|---|---|
| IE61294B1 (en) | 1994-10-19 |
| JPH0648980B2 (ja) | 1994-06-29 |
| GR3007158T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1993-07-30 |
| IE882407L (en) | 1989-02-06 |
| EP0302692A3 (en) | 1990-02-14 |
| NZ225583A (en) | 1991-07-26 |
| PT88178A (pt) | 1989-06-30 |
| EP0302692A2 (en) | 1989-02-08 |
| PT88178B (pt) | 1995-03-01 |
| KR890003407A (ko) | 1989-04-14 |
| DK437988A (da) | 1989-04-04 |
| ATE84067T1 (de) | 1993-01-15 |
| ES2042751T3 (es) | 1993-12-16 |
| DK173215B1 (da) | 2000-04-03 |
| JPS6451080A (en) | 1989-02-27 |
| DE3877082D1 (de) | 1993-02-11 |
| US5521082A (en) | 1996-05-28 |
| DK437988D0 (da) | 1988-08-05 |
| EP0302692B1 (en) | 1992-12-30 |
| KR970001711B1 (ko) | 1997-02-14 |
| ZA885726B (en) | 1989-04-26 |
| DE3877082T2 (de) | 1993-06-03 |
| IL87257A0 (en) | 1988-12-30 |
| CY1773A (en) | 1995-10-20 |
| AU2051888A (en) | 1989-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU612168B2 (en) | Novel process for purification of hepatitis a virions | |
| AU2020294216B2 (en) | Methods of detection and removal of rhabdoviruses from cell lines | |
| CA2197683C (en) | Method for preparing an influenza virus, antigens obtained and applications thereof | |
| Kalnciema et al. | Potato virus Y-like particles as a new carrier for the presentation of foreign protein stretches | |
| KR20180097558A (ko) | 지카 바이러스 백신 | |
| EP0522291B1 (en) | Process for purifying hepatitis a virus (HAV), virus thus purified and vaccine compositions containing it | |
| Emerson et al. | cDNA clone of hepatitis A virus encoding a virulent virus: induction of viral hepatitis by direct nucleic acid transfection of marmosets | |
| US7431933B2 (en) | Hepatitis B virus DNA polymerase and surface antigen variants and methods of using same | |
| Gilead et al. | Characterization of the Tumorlike (T) Antigen Induced by Type 12 Adenovirus: I. Purification of the Antigen from Infected KB Cells and a Hamster Tumor Cell Line | |
| JP6734137B2 (ja) | インビトロにおいて生成したウイルスの精製方法及びウイルスのクリアランスアッセイ | |
| EP0468702A2 (en) | Novel process for purification of Hepatitis-A virus capsids | |
| US4136168A (en) | Process for the preparation of neuraminidase from viral sources and methods of utilizing same | |
| HK32794A (en) | Novel process for purification of hepatitis a virions | |
| US4195076A (en) | Process for the preparation of hemagglutinin from viral sources and methods of utilizing same | |
| CN119286892A (zh) | 一种重组mRNA、DNA分子、药物组合物、疫苗及制备方法 | |
| RO111472B1 (ro) | Procedeu de purificare a capsidelor virusului de hepatită A | |
| KR20210061939A (ko) | 구제역 바이러스 백신 항원의 순도 증가 방법 | |
| CN120442658A (zh) | 一种猪圆环病毒4型环状dna片段的构建方法、猪圆环病毒4型的制备方法及应用 | |
| RU2417262C1 (ru) | Штамм "белгородский-03" вируса геморрагической болезни кроликов для изготовления вакцинных и диагностических препаратов | |
| CN113293147A (zh) | 一种新型冠状病毒的规模化纯化方法 | |
| HU203675B (en) | Process for producing sub-unit-vaccine against aujeszky-disease of pigs | |
| CN109943536A (zh) | 一种戊型肝炎病毒、培养方法及其灭活疫苗的制备方法 | |
| CA2070903A1 (en) | Process for purifying hepatitis a virus (hav), virus thus purified and vaccine compositions containing it | |
| HK1227433B (en) | Methods of detection and removal of rhabdoviruses from cell lines | |
| HK1227433A1 (en) | Methods of detection and removal of rhabdoviruses from cell lines |